In Brief: ICN Pharmaceuticals
Executive Summary
ICN Pharmaceuticals: A 1996 Securities & Exchange Commission investigation focused on mistatements by the company regarding its hepatitis C NDA for Virazole (ribivarin), not combination use with interferon ("The Pink Sheet" Jan. 26, In Brief)...
ICN Pharmaceuticals: A 1996 Securities & Exchange Commission investigation focused on mistatements by the company regarding its hepatitis C NDA for Virazole (ribivarin), not combination use with interferon ("The Pink Sheet" Jan. 26, In Brief).... |